TraffikGene

TraffikGene is a Spanish biotechnology company and a spin-off from the University of Santiago de Compostela (CiQUS) that focuses on the development of innovative peptide-based delivery systems for nucleic acids. The company's proprietary technology provides a versatile and efficient alternative to traditional lipid nanoparticles (LNPs) for the transport of mRNA, siRNA, and CRISPR components. By utilizing specialized peptides, TraffikGene's platform enhances cellular uptake and endosomal escape, ensuring that therapeutic cargoes reach their intracellular targets with high precision and low toxicity. Their business model centers on the development of an internal pipeline and strategic collaborations with pharmaceutical partners to enable next-generation gene therapies and vaccines. The company is primarily active in the fields of oncology, infectious diseases, and rare genetic disorders.